⚠️ Research chemical. Not for human administration. All data referenced is from preclinical studies (in vitro / animal models).
⏱️ Reading time: ~14 min | Updated: May 19, 2026
KPV Peptide Research: The Anti-Inflammatory Tripeptide Derived from Alpha-MSH
Three amino acids. One potent suppressor of NF-κB. When researchers at Emory University quantified how efficiently the intestinal transporter PepT1 shuttled Lys-Pro-Val directly into inflamed epithelial cells, they found something that most larger peptides can't do: near-complete upstream blockade of the inflammatory cascade without touching the adaptive immune system. That 2008 paper in Gastroenterology rewrote how the field thinks about size vs. potency in anti-inflammatory peptide research (Dalmasso G et al., PMID 18061177).
KPV doesn't get the press BPC-157 gets. It doesn't generate the controversy LL-37 does. But in the narrow domain it's been studied — intestinal inflammation, cutaneous repair, NF-κB-driven cytokine storms — the preclinical data are unusually clean.
What Is KPV?
KPV is a synthetic tripeptide with the sequence Lysine-Proline-Valine. It corresponds to positions 11–13 of alpha-melanocyte-stimulating hormone (α-MSH), a 13-amino-acid neuropeptide cleaved from proopiomelanocortin (POMC). The full C-terminal tripeptide of α-MSH — KPV — is what most researchers believe drives the anti-inflammatory activity of the parent molecule.
This matters for two reasons. First, α-MSH has documented anti-inflammatory effects across multiple organ systems, but its size limits oral bioavailability and complicates delivery. KPV, at three amino acids, sidesteps both problems. Second, the fragment retains activity through a distinct mechanism from the full α-MSH — one that doesn't require binding to classical melanocortin receptors (MC1R through MC5R) with the same affinity. The downstream pathway target is shared: NF-κB suppression. The upstream pathway differs.
In preclinical literature, KPV appears in research contexts covering:
- Inflammatory bowel disease (IBD), specifically colitis models
- Skin inflammation and wound healing
- Airway inflammation (early-stage research)
- Keratinocyte protection under oxidative and inflammatory stress
It is not commercially available as a licensed pharmaceutical. Its research classification places it in the same regulatory space as BPC-157 and TB-500 — active compounds with substantial preclinical data but no completed human clinical trials.
Molecular Profile
| Parameter | Value |
|---|---|
| Full name | Lysine-Proline-Valine |
| Abbreviation | KPV |
| Origin | α-MSH fragment (positions 11–13) |
| CAS number | 67727-97-3 (free acid form) |
| Molecular formula | C₁₄H₂₆N₄O₄ |
| Molecular weight | ~314.38 g/mol |
| Sequence (1-letter) | K-P-V |
| IUPAC | L-Lysyl-L-Prolyl-L-Valine |
| Solubility | Water-soluble; stable in PBS at physiological pH |
| Primary transporter | PepT1 (SLC15A1) |
At 314 Da, KPV is one of the smallest bioactive peptides in current research interest. For comparison: BPC-157 is 1419 Da, TB-500 fragment is ~2888 Da. This size differential directly affects pharmacokinetics — and PepT1-mediated uptake makes KPV uniquely suitable for oral delivery studies, something most research peptides cannot claim.
Mechanism of Action: The NF-κB Axis
The core mechanism is direct inhibition of nuclear factor kappa-B (NF-κB) signaling. NF-κB is the master transcription factor for pro-inflammatory cytokine production — IL-1β, TNF-α, IL-6, IL-8. When activated (typically via TLR4/TLR2 or cytokine receptor signaling), NF-κB translocates to the nucleus and drives expression of the entire inflammatory gene network.
KPV suppresses this cascade at multiple points:
1. IκB Kinase Inhibition
KPV appears to block IKK-β phosphorylation, preventing the degradation of IκBα — the cytoplasmic anchor that keeps NF-κB inactive. Without IκBα degradation, p65/p50 subunits remain sequestered and cannot translocate. This is the most upstream point of intervention in the cascade.
2. Direct Cytokine Suppression
Even downstream of NF-κB, KPV reduces secreted levels of IL-1β and TNF-α in stimulated macrophage and epithelial cell models. Whether this reflects a parallel pathway or is entirely IKK-mediated remains under investigation.
3. Epithelial Barrier Reinforcement
Alpha-MSH and its fragments — including KPV — protect tight junction proteins (ZO-1, occludin, claudin-3) under cytokine challenge. This is particularly relevant in IBD research contexts where barrier dysfunction drives disease perpetuation (Váradi J et al., PLoS One 2017, PMID 28103316).
4. POMC / Melanocortin-Independent Activity
Unlike full α-MSH, KPV does not require classical MC1R binding to exert anti-inflammatory effects in intestinal epithelial cells. This suggests a receptor-independent or lower-affinity receptor-dependent mechanism — an area where the research remains genuinely open.
PepT1: The Oral Bioavailability Advantage
PepT1 (SLC15A1) is a proton-coupled oligopeptide transporter expressed in the small intestinal brush border. It evolved to absorb di- and tripeptides from dietary protein — which means KPV fits its substrate profile almost perfectly.
The 2008 Dalmasso study was the first to systematically demonstrate PepT1-mediated KPV uptake in colonic epithelial cells, and to show that this uptake was functionally linked to reduced NF-κB activation. Critically, the study showed this in both normal and inflamed mucosa — and PepT1 expression is upregulated in active IBD, meaning inflamed tissue actually concentrates more KPV than healthy tissue would. This inflammatory upregulation of the delivery mechanism is one of the more elegant features of KPV pharmacology (Dalmasso G et al., Gastroenterology 2008, PMID 18061177).
This property has driven a significant portion of subsequent KPV delivery research. If PepT1 actively concentrates KPV at sites of gut inflammation, the logical direction is oral nanoparticle formulations designed to survive gastric pH and reach the distal ileum/colon intact. That's exactly what the Xiao et al. (2017) and Laroui et al. (2010) studies explored.
Preclinical Research: IBD & Colitis Models
TNBS-Induced Colitis (Murine)
The trinitrobenzene sulfonic acid (TNBS) model is the gold standard for Th1-driven colitis research. Multiple KPV studies have used this model to assess colon inflammation, crypt damage, and cytokine profiles.
Key findings across studies:
- Reduced macroscopic damage scores: KPV-treated animals showed significant reduction in colon shortening, ulceration, and wall thickening compared to controls
- Lower histological inflammation scores: Fewer infiltrating neutrophils and macrophages in the lamina propria
- Cytokine suppression: Measured IL-1β and TNF-α levels in colon tissue were consistently lower in KPV groups
- NF-κB p65 nuclear translocation: Immunohistochemistry showed reduced p65 nuclear signal in colonocytes of KPV-treated mice
The self-cross-linked hydrogel study by Sun et al. (2021) is particularly notable: by embedding KPV in a cysteamine-grafted γ-polyglutamic acid hydrogel, researchers extended local residence time in the colon, maintained anti-inflammatory activity over 72h, and demonstrated reduced TNBS-induced mucosal damage equivalent to mesalamine controls at lower effective concentrations (PMID 34547895).
DSS Model (Dextran Sulfate Sodium)
The DSS colitis model more closely mimics the epithelial barrier damage component of ulcerative colitis. The 2024 nanoparticle platform study by Marotti et al. used a combined mucosal healing + immunomodulation strategy, with KPV as the anti-inflammatory cargo. Results showed mucosal healing acceleration alongside cytokine normalization — an effect not seen with either component alone (PMID 37859689).
What the IBD data means for researchers
Four independent research groups, three different model systems, consistent directional findings. The KPV IBD dataset is not as large as BPC-157's literature, but it is more mechanistically focused. Each study tested a hypothesis about delivery or mechanism rather than simply asking "does it reduce inflammation?" — which makes the positive results more interpretable.
Skin & Wound Healing Research
Keratinocyte Protection
A 2025 study by Sung et al. examined KPV's effects on human keratinocytes (HaCaT cells) exposed to fine particulate matter (PM2.5). KPV significantly attenuated PM2.5-induced apoptosis, ROS generation, and inflammatory cytokine release. The proposed mechanism was dual: NF-κB suppression downstream of oxidative stress signaling, and upregulation of the Nrf2 antioxidant pathway. This positions KPV as relevant not just for IBD-type inflammation but for skin conditions with inflammatory and oxidative components (PMID 40073467).
Melanocortin Pathway in Wound Healing
The melanocortin system — and specifically the C-terminal tripeptide region of α-MSH represented by KPV — has been studied as a potential wound healing modulator. A 2019 review by Böhm and Luger examined the body of evidence for melanocortin peptides in cutaneous wound repair, noting that anti-inflammatory activity at the wound site combined with effects on keratinocyte migration and proliferation make this class pharmacologically interesting for dermatological applications (PMID 30661264).
Role of Tripeptides in Skin Regeneration
A comprehensive 2025 review in International Journal of Medical Sciences examined the role of tripeptides specifically in wound healing and skin regeneration. KPV was highlighted as one of the most studied tripeptides in this context, with mechanisms including ECM modulation, cytokine attenuation, and epithelial migration support (Adnan SB et al., PMID 41209547).
KPV vs LL-37 vs BPC-157: Comparative Analysis
This is the cross-analysis that most review articles don't bother to make — because the compounds are studied by separate research communities. But for researchers studying inflammatory pathways, the comparison is operationally useful.
↔ Scroll horizontally to view the full table on mobile.
| Parameter | KPV (Lys-Pro-Val) | LL-37 (Cathelicidin) | BPC-157 (Body Protective Compound) |
|---|---|---|---|
| Type | Synthetic tripeptide (3 AA) — α-MSH fragment | Host defense peptide (37 AA) — cathelicidin family | Synthetic pentadecapeptide (15 AA) — gastric juice origin |
| MW (Da) | 314 Da | ~4,493 Da | 1,419 Da |
| Primary mechanism | Direct NF-κB inhibition via IKK-β blockade; PepT1 uptake | TLR4/TLR9 modulation; membrane disruption (antimicrobial); FPRL1 binding | VEGFR2/eNOS upregulation; angiogenesis; GI cytoprotection |
| IL-6 modulation | ↓↓ (direct NF-κB transcription block) | Context-dependent: ↓ (anti-inflam. doses) / ↑ (supra-physiological) | ↓ (indirect; secondary to VEGFR2 signaling normalization) |
| TNF-α modulation | ↓↓ (consistent across IBD models) | ↓ at physiological conc.; dual-function at supra-physiological | ↓ (preclinical GI/muscle models) |
| Direct NF-κB inhibitor? | ✅ Yes — most direct of the three | Indirect (TLR modulation → NF-κB downstream) | Indirect (VEGFR2/prostaglandin crosstalk) |
| Primary research application | IBD / colitis; skin inflammation; keratinocyte protection | Wound healing; antimicrobial; innate immunity modulation | Tendon/ligament; GI repair; muscle; CNS (exploratory) |
| Oral bioavailability | High (PepT1-mediated intestinal uptake) | Poor (rapidly degraded; primarily topical/injectable) | Moderate (some oral preclinical data; injectable preferred) |
| Antimicrobial activity | Not demonstrated | Yes — broad-spectrum membrane disruption | Not a primary focus |
| Highest evidence level | In vivo murine models (colitis, skin) | In vivo wound healing; Phase I/II (wound, acne) | In vivo rodent models (extensive); no human trials |
What this table tells researchers: KPV is the most upstream NF-κB suppressor of the three. LL-37 has broader antimicrobial applicability but more complex dose-response at the cytokine level. BPC-157's anti-inflammatory activity is largely secondary to its tissue-repair mechanisms. For pure inflammatory cytokine modulation research — particularly in gut epithelium — KPV's mechanistic clarity and oral bioavailability profile give it a distinct research niche.
Delivery Systems Under Investigation
One of the most active areas of KPV research is formulation science — how to get an aqueous-soluble tripeptide to the right tissue compartment without losing it to enzymatic degradation.
Hyaluronic Acid Nanoparticles (2017)
Xiao et al. developed HA-functionalized nanoparticles for oral KPV delivery targeting colonic CD44+ epithelial cells. The hyaluronic acid coating served two functions: protection from gastric/small intestinal peptidase activity, and active targeting via CD44 receptor binding, which is overexpressed on inflamed colonic epithelium. In DSS-induced colitis mice, oral KPV-HA nanoparticles significantly reduced DAI scores, colon shortening, and inflammatory cytokines compared to free KPV at equivalent dose (Xiao B et al., Mol Ther 2017, PMID 28143741). The nanoparticle KPV outperformed free KPV not because the compound was more potent, but because it survived delivery.
Polysaccharide Hydrogel Formulation (2010)
Laroui et al. encapsulated KPV in a polysaccharide hydrogel bead system designed for colon-targeted release. The hydrogel protected the peptide through the upper GI tract and demonstrated significant anti-inflammatory activity in a TNBS colitis model, with reduced MPO activity (neutrophil infiltration marker) and lower IL-1β levels compared to free drug (Laroui H et al., Gastroenterology 2010, PMID 19909746).
Self-Cross-Linked Hydrogel (2021)
The Sun et al. approach extended this further using cysteamine-grafted γ-PGA as the matrix. The hydrogel formed a sustained-release depot in the colon, releasing KPV over 72h with retained biological activity. This formulation approach reduced the effective dose required for significant anti-inflammatory effect compared to bolus free peptide — suggesting that local sustained exposure is pharmacodynamically more favorable than single-dose spikes (PMID 34547895).
Topical Delivery (Skin Research)
For skin applications, KPV research has mostly used standard aqueous and gel-based formulations. The simplicity of the molecule — small, water-soluble, stable — makes topical formulation relatively straightforward compared to the oral IBD challenge. The 2025 skin/keratinocyte study demonstrated activity at concentrations achievable topically (PMID 40073467).
Stability, Storage & Quality Parameters
KPV is a short, linear tripeptide. Stability is generally good relative to larger peptides, with some key considerations:
- Lyophilized powder: Stable at −20°C for extended periods. The proline residue adds proteolytic resistance vs. standard dipeptides.
- In solution: Use within 2–4 weeks at 4°C with preservatives. For longer storage: −80°C. Avoid repeated freeze-thaw cycles.
- pH stability: Maintains structural integrity at physiological pH (7.2–7.4) and acidic pH (≥3) — adequate gastric survival for oral delivery research.
- Purity threshold: ≥98% HPLC purity + mass spec confirmation (~314.38 Da) for research-grade material.
For reconstitution protocols applicable to KPV and similar water-soluble peptides, see our peptide reconstitution guide. For CoA verification methodology, see our guide on how to read a peptide CoA.
For vendor qualification criteria and sourcing guidance, our 2026 research peptide sourcing guide covers KPV-relevant considerations including third-party HPLC, endotoxin testing, and mass spec documentation requirements.
Researchers sourcing KPV for preclinical studies can browse available research compounds — including documentation standards and purity certificates — in our research peptide catalog.
FAQ
What is KPV peptide?
KPV (Lysine-Proline-Valine) is a synthetic tripeptide derived from positions 11–13 of alpha-melanocyte-stimulating hormone (α-MSH). With a molecular weight of approximately 314 Da (CAS 67727-97-3), it is one of the smallest known anti-inflammatory peptides studied in preclinical models. It is a research chemical not approved for human use.
How does KPV reduce inflammation?
KPV's primary mechanism in preclinical models is inhibition of IκB kinase-β (IKK-β) phosphorylation, which prevents degradation of IκBα and thereby blocks NF-κB nuclear translocation. This suppresses transcription of pro-inflammatory genes including TNF-α, IL-1β, and IL-6. Additionally, KPV enters intestinal epithelial cells via the PepT1 transporter, which is overexpressed at sites of gut inflammation — concentrating the compound precisely where activity is needed.
What is the difference between KPV and alpha-MSH?
Alpha-MSH is a 13-amino-acid peptide that exerts anti-inflammatory effects primarily through melanocortin receptor binding (especially MC1R). KPV is its C-terminal tripeptide (positions 11–13) and retains anti-inflammatory activity through a mechanism that is partially receptor-independent. The critical practical difference is size: at 314 Da, KPV has markedly better oral bioavailability via the PepT1 transporter, whereas full α-MSH requires parenteral delivery for consistent systemic exposure in research models.
What research models have been used to study KPV?
The most common preclinical models include: TNBS-induced colitis (Th1-driven murine colitis), DSS-induced colitis (barrier damage model), human colonic epithelial cell lines (Caco-2, HCT116), and HaCaT keratinocyte models for skin research. All KPV research to date is preclinical — cell culture and animal studies only. No human clinical trials have been completed.
How does KPV compare to BPC-157 in anti-inflammatory research?
The compounds have distinct mechanisms. KPV is a direct, upstream NF-κB inhibitor — it works by blocking IKK-β before the entire cytokine transcription cascade activates. BPC-157's anti-inflammatory effects are secondary to its tissue-repair mechanisms (VEGFR2/eNOS upregulation, angiogenesis), making it more relevant for structural repair models than pure cytokine suppression studies. For IBD and epithelial inflammatory models specifically, KPV's PepT1-mediated uptake and NF-κB directness give it a more focused research application.
Is KPV related to LL-37?
No structural relationship. KPV comes from the melanocortin (POMC) system; LL-37 is a human cathelicidin host defense peptide (37 amino acids) from the innate immune system. They share anti-inflammatory phenotypes in certain models but via entirely different mechanisms. LL-37 also has strong antimicrobial activity through membrane disruption — something KPV has not demonstrated.
What is the purity standard for research-grade KPV?
Research-grade KPV should meet ≥98% purity by HPLC, with mass spectrometry confirmation of the expected molecular weight (~314.38 Da). For in vivo rodent studies, endotoxin testing (≤1 EU/mg by LAL assay) is essential to rule out LPS-driven confounders in inflammation experiments.
References
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. PMID 18061177
- Laroui H, Dalmasso G, Nguyen HT, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010;138(3):843–853. PMID 19909746
- Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25(7):1628–1640. PMID 28143741
- Sun J, Xue P, Liu J, et al. Self-cross-linked hydrogel of cysteamine-grafted γ-polyglutamic acid stabilized tripeptide KPV for alleviating TNBS-induced colitis. ACS Biomater Sci Eng. 2021;7(10):4859–4869. PMID 34547895
- Marotti V, Xu Y, Bohns Michalowski C, et al. A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment. Bioact Mater. 2024;35:487–502. PMID 37859689
- Sung J, Ju SY, Park S, et al. Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress. Tissue Cell. 2025;93:102724. PMID 40073467
- Váradi J, Harazin A, Fenyvesi F, et al. Alpha-melanocyte stimulating hormone protects against cytokine-induced barrier damage in Caco-2 intestinal epithelial monolayers. PLoS One. 2017;12(5):e0170537. PMID 28103316
- Adnan SB, Maarof M, Fauzi MB. Exploring the role of tripeptides in wound healing and skin regeneration: a comprehensive review. Int J Med Sci. 2025;22(4):823–841. PMID 41209547
- Böhm M, Luger T. Are melanocortin peptides future therapeutics for cutaneous wound healing? Exp Dermatol. 2019;28(12):1375–1382. PMID 30661264
- Gómez-SanMiguel AB, Villanúa MÁ, Martín AI, et al. D-TRP(8)-γMSH prevents the effects of endotoxin in rat skeletal muscle cells through TNFα/NF-κB signalling pathway. PLoS One. 2016;11(5):e0155920. PMID 27177152
All information is for research purposes only. KPV is not approved for human administration. Research use only.

